Related Experiment Video
Updated: Jun 4, 2026
06:16
Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
Public and decision maker stated preferences for pharmaceutical subsidy decisions: a pilot study
Jennifer A Whitty1, Paul A Scuffham, Sharyn R Rundle-Thiele
1School of Medicine, Griffith University, Logan Campus, University Drive, Meadowbrook, QLD 4131, Australia. j.whitty@griffith.edu.au
Applied Health Economics and Health Policy
|February 22, 2011
Summary
Public and decision-makers share similar preferences for pharmaceutical subsidies, prioritizing survival, quality of life, and treatment effectiveness, especially for severe illnesses. This research bridges the gap in understanding societal preferences for drug funding.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Public Health
Background:
- Public preferences are crucial for pharmaceutical subsidy decisions.
- Limited research exists on public preferences for pharmaceutical funding.
- No studies have compared public preferences with those of decision-making bodies.
Purpose of the Study:
- To evaluate the consistency between public and decision-maker preferences for pharmaceutical subsidies.
- To pilot a discrete-choice experiment (DCE) for assessing these preferences.
Main Methods:
- A discrete-choice experiment (DCE) was employed.
- Elicited preferences for survival gains, quality of life (QOL), response success, and costs.
- Assessed the impact of illness severity on preferences.
- Administered to the Australian public and pharmaceutical decision-makers.
- Analyzed using a mixed logit model.
Main Results:
- Both public and decision-makers favored pharmaceuticals offering increased survival, QOL, and response success.
- Reduced costs and uncertainty positively influenced funding likelihood for decision-makers.
- Both groups prioritized funding for treatments of severe illnesses.
Conclusions:
- This study provides a foundation for understanding societal preferences in pharmaceutical funding.
- Highlights the need for further research on decision criteria and contextual impacts.
- Informs future policy on aligning pharmaceutical subsidy decisions with public preferences in Australia and globally.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:09Decision Making: P-value Method
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.